JP2010529038A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010529038A5 JP2010529038A5 JP2010510505A JP2010510505A JP2010529038A5 JP 2010529038 A5 JP2010529038 A5 JP 2010529038A5 JP 2010510505 A JP2010510505 A JP 2010510505A JP 2010510505 A JP2010510505 A JP 2010510505A JP 2010529038 A5 JP2010529038 A5 JP 2010529038A5
- Authority
- JP
- Japan
- Prior art keywords
- patients
- imatinib
- leukemia
- treatment
- resistance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 9
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 6
- 229960002411 imatinib Drugs 0.000 description 6
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 5
- 230000035772 mutation Effects 0.000 description 4
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229960003736 bosutinib Drugs 0.000 description 1
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940080856 gleevec Drugs 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93265007P | 2007-06-01 | 2007-06-01 | |
| US60/932,650 | 2007-06-01 | ||
| PCT/US2008/065215 WO2008150957A2 (en) | 2007-06-01 | 2008-05-30 | Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014016309A Division JP2014111629A (ja) | 2007-06-01 | 2014-01-31 | ４−アミノキノリン−３−カルボニトリルを使用するイマチニブ耐性白血病の処置 |
| JP2015229117A Division JP2016074700A (ja) | 2007-06-01 | 2015-11-24 | ４−アミノキノリン−３−カルボニトリルを使用するイマチニブ耐性白血病の処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010529038A JP2010529038A (ja) | 2010-08-26 |
| JP2010529038A5 true JP2010529038A5 (https=) | 2016-01-14 |
| JP5888853B2 JP5888853B2 (ja) | 2016-03-22 |
Family
ID=39639071
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010510505A Active JP5888853B2 (ja) | 2007-06-01 | 2008-05-30 | ４−アミノキノリン−３−カルボニトリルを使用するイマチニブ耐性白血病の処置 |
| JP2014016309A Pending JP2014111629A (ja) | 2007-06-01 | 2014-01-31 | ４−アミノキノリン−３−カルボニトリルを使用するイマチニブ耐性白血病の処置 |
| JP2015229117A Pending JP2016074700A (ja) | 2007-06-01 | 2015-11-24 | ４−アミノキノリン−３−カルボニトリルを使用するイマチニブ耐性白血病の処置 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014016309A Pending JP2014111629A (ja) | 2007-06-01 | 2014-01-31 | ４−アミノキノリン−３−カルボニトリルを使用するイマチニブ耐性白血病の処置 |
| JP2015229117A Pending JP2016074700A (ja) | 2007-06-01 | 2015-11-24 | ４−アミノキノリン−３−カルボニトリルを使用するイマチニブ耐性白血病の処置 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US11103497B2 (https=) |
| EP (4) | EP2152267A2 (https=) |
| JP (3) | JP5888853B2 (https=) |
| KR (1) | KR101493543B1 (https=) |
| CN (1) | CN101686973B (https=) |
| AU (1) | AU2008260070B9 (https=) |
| BR (1) | BRPI0812355A2 (https=) |
| CA (3) | CA2964162C (https=) |
| CL (1) | CL2008001577A1 (https=) |
| CY (2) | CY1115251T1 (https=) |
| DK (2) | DK2478905T3 (https=) |
| ES (2) | ES2881391T3 (https=) |
| HU (1) | HUE055524T2 (https=) |
| IL (1) | IL202407A0 (https=) |
| MX (1) | MX2009013069A (https=) |
| PA (1) | PA8782301A1 (https=) |
| PL (2) | PL2478905T3 (https=) |
| PT (2) | PT2478905E (https=) |
| RU (1) | RU2464026C2 (https=) |
| SI (2) | SI2478905T1 (https=) |
| TW (1) | TW200908982A (https=) |
| WO (1) | WO2008150957A2 (https=) |
| ZA (1) | ZA200908480B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2964162C (en) | 2007-06-01 | 2019-12-31 | Wyeth Llc | Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles having mutation in the bcrabl gene |
| SG192769A1 (en) | 2011-03-04 | 2013-09-30 | Glaxosmithkline Ip No 2 Ltd | Amino-quinolines as kinase inhibitors |
| TWI547494B (zh) | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
| AR092529A1 (es) | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento |
| AR092530A1 (es) | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento |
| RU2662810C2 (ru) | 2013-02-21 | 2018-07-31 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Хиназолины в качестве ингибиторов киназы |
| KR101733665B1 (ko) | 2015-05-06 | 2017-05-10 | 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 | 진세노사이드 Ｆ1 또는 Ｒｇ3을 유효성분으로 포함하는 글리벡 내성 백혈병 예방 또는 치료용 약학 조성물 |
| JP2022544700A (ja) * | 2019-08-22 | 2022-10-20 | バイオヘイブン・セラピューティクス・リミテッド | 筋萎縮性側索硬化症および関連障害の治療のためにｔｄｐ－４３に結合する分子 |
| CN115944636A (zh) * | 2022-11-01 | 2023-04-11 | 华南师范大学 | 博舒替尼在抑制i-motif结构上的应用 |
| WO2025024311A2 (en) * | 2023-07-21 | 2025-01-30 | Icahn School Of Medicine At Mount Sinai | G9a/glp inhibitors and methods of use |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6297258B1 (en) | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| AU2002245296B2 (en) * | 2001-01-25 | 2006-12-21 | Bristol-Myers Squibb Company | Methods of administering epothilone analogs for the treatment of cancer |
| PT2017335E (pt) | 2001-10-05 | 2011-03-02 | Novartis Ag | Domínios da cinase abl mutados |
| TWI275390B (en) * | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
| US20050010780A1 (en) * | 2003-07-09 | 2005-01-13 | Kane John Richard | Method and apparatus for providing access to personal information |
| EP1680119A1 (en) * | 2003-11-06 | 2006-07-19 | Wyeth | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml) |
| NL1031674C2 (nl) | 2005-04-25 | 2007-04-26 | Pfizer | Antilichamen tegen myostatine. |
| DE602006014540D1 (en) * | 2005-05-16 | 2010-07-08 | Irm Llc | Pyrrolopyridinderivate als proteinkinaseinhibitoren |
| EP1904654A2 (en) | 2005-07-15 | 2008-04-02 | Brystol-Myers Squibb Company | Methods of identifying and treating individuals exhibiting mutant src kinase polypeptides |
| BRPI0616923A2 (pt) | 2005-10-06 | 2011-07-05 | Lilly Co Eli | anticorpos monoclonais, seus usos e composição farmacêutica |
| EP1948820A2 (en) * | 2005-11-04 | 2008-07-30 | Bristol-Myers Squibb Pharma Company | T315a and f317i mutations of bcr-abl kinase domain |
| CA2964162C (en) | 2007-06-01 | 2019-12-31 | Wyeth Llc | Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles having mutation in the bcrabl gene |
-
2008
- 2008-05-30 CA CA2964162A patent/CA2964162C/en active Active
- 2008-05-30 SI SI200831212T patent/SI2478905T1/sl unknown
- 2008-05-30 WO PCT/US2008/065215 patent/WO2008150957A2/en not_active Ceased
- 2008-05-30 EP EP08769857A patent/EP2152267A2/en not_active Withdrawn
- 2008-05-30 MX MX2009013069A patent/MX2009013069A/es active IP Right Grant
- 2008-05-30 TW TW097120369A patent/TW200908982A/zh unknown
- 2008-05-30 PT PT121606388T patent/PT2478905E/pt unknown
- 2008-05-30 HU HUE15191756A patent/HUE055524T2/hu unknown
- 2008-05-30 PT PT151917564T patent/PT3002009T/pt unknown
- 2008-05-30 PL PL12160638T patent/PL2478905T3/pl unknown
- 2008-05-30 CN CN2008800219346A patent/CN101686973B/zh active Active
- 2008-05-30 EP EP15191756.4A patent/EP3002009B1/en active Active
- 2008-05-30 RU RU2009144128/15A patent/RU2464026C2/ru active
- 2008-05-30 ES ES15191756T patent/ES2881391T3/es active Active
- 2008-05-30 EP EP12160638.8A patent/EP2478905B1/en active Active
- 2008-05-30 PA PA20088782301A patent/PA8782301A1/es unknown
- 2008-05-30 SI SI200832178T patent/SI3002009T1/sl unknown
- 2008-05-30 CA CA2868899A patent/CA2868899C/en active Active
- 2008-05-30 KR KR1020097027540A patent/KR101493543B1/ko active Active
- 2008-05-30 DK DK12160638.8T patent/DK2478905T3/da active
- 2008-05-30 CL CL200801577A patent/CL2008001577A1/es unknown
- 2008-05-30 AU AU2008260070A patent/AU2008260070B9/en active Active
- 2008-05-30 ES ES12160638.8T patent/ES2477567T3/es active Active
- 2008-05-30 EP EP14167958.9A patent/EP2777704A3/en not_active Withdrawn
- 2008-05-30 BR BRPI0812355-1A2A patent/BRPI0812355A2/pt not_active Application Discontinuation
- 2008-05-30 US US12/129,935 patent/US11103497B2/en active Active
- 2008-05-30 DK DK15191756.4T patent/DK3002009T3/da active
- 2008-05-30 JP JP2010510505A patent/JP5888853B2/ja active Active
- 2008-05-30 PL PL15191756T patent/PL3002009T3/pl unknown
- 2008-05-30 CA CA2688467A patent/CA2688467C/en active Active
-
2009
- 2009-11-29 IL IL202407A patent/IL202407A0/en unknown
- 2009-11-30 ZA ZA200908480A patent/ZA200908480B/xx unknown
-
2014
- 2014-01-31 JP JP2014016309A patent/JP2014111629A/ja active Pending
- 2014-06-03 CY CY20141100395T patent/CY1115251T1/el unknown
-
2015
- 2015-11-24 JP JP2015229117A patent/JP2016074700A/ja active Pending
-
2021
- 2021-08-03 CY CY20211100693T patent/CY1124391T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010529038A5 (https=) | ||
| Kastritis et al. | A randomized phase III trial of melphalan and dexamethasone (MDex) versus bortezomib, melphalan and dexamethasone (BMDex) for untreated patients with AL amyloidosis | |
| MY153198A (en) | Inhibitors of protein aggregation | |
| RU2016141934A (ru) | Ингибиторы циклин-зависимой киназы 7 (cdk7) | |
| HRP20050318A2 (en) | Pyrimidinone derivatives as therapeutic agents against acute and chronic inflamatory, ischaemic and remodelling processes | |
| JP2010285439A5 (https=) | ||
| IL184673A0 (en) | COMPOUNDS POSSESSING B-Raf INHIBITORY ACTIVITY, PROCESSES FOR THEIR MANUFACTURE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE THEREOF IN THE MANUFACTURE OF MEDICAMENTS FOR PRODUCING AN ANTI-CANCER EFFECT IN WARM-BLOODED ANIMALS | |
| JP2009513660A5 (https=) | ||
| ATE494899T1 (de) | Zusammensetzung bestehend aus phy906 und chemotherapeutika | |
| TW200630105A (en) | Herbal composition PHY906 and its use in chemotherapy | |
| CN110799501A (zh) | 一种食欲素受体拮抗剂的晶型及其制备方法和用途 | |
| JP2013533287A5 (https=) | ||
| DE602006010834D1 (de) | Neue thiophensulfoximine zur behandlung von komplementvermittelten krankheiten und leiden | |
| HUE055524T2 (hu) | A bcrabl génben 1457T>C mutációt tartalmazó, imatinibbel szemben ellenálló krónikus mielogén leukémia kezelése bozutinib vegyület alkalmazásával | |
| WO2007120726A3 (en) | Compositions and methods related to rad51 inactivation in the treatment of neoplastic diseases, and especially cml | |
| IL195441A0 (en) | Use of trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthaleneamine and its formamide in the preparation of medicaments for the treatment of pain disorders | |
| MXPA05013200A (es) | Derivados de estaurosporina para sindrome hipereosinofilico. | |
| EP4455145A3 (en) | Piperidinyl nociceptin receptor compounds | |
| JP2009523456A5 (https=) | ||
| JP2019530711A5 (https=) | ||
| Paquette et al. | A phase I study of XL019, a selective JAK2 inhibitor, in patients with polycythemia vera | |
| BRPI0504758A (pt) | miméticos de interleucina-8 e métodos para usá-los em prevenção, tratamento, diagnóstico, e melhora dos sintomas de uma doença | |
| DE602006012332D1 (de) | Kombination von verbindungen, die bei der behandlung von atemwegserkrankungen verwendet werden können, insbesondere bei chronisch obstruktiver lungenerkrankung (copd) und asthma | |
| JP2010526884A5 (https=) | ||
| Tanaka et al. | Activity of the multi-targeted kinase inhibitor, AT9283 on Imatinib-resistant CML models |